These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 30170190)

  • 1. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
    Wey JS; Fan F; Gray MJ; Bauer TW; McCarty MF; Somcio R; Liu W; Evans DB; Wu Y; Hicklin DJ; Ellis LM
    Cancer; 2005 Jul; 104(2):427-38. PubMed ID: 15952180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.
    Ceci C; Atzori MG; Lacal PM; Graziani G
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.
    Jayasinghe C; Simiantonaki N; Kirkpatrick CJ
    BMC Cancer; 2015 Mar; 15():104. PubMed ID: 25880726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
    Lacal PM; Ruffini F; Pagani E; D'Atri S
    Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.